KNX News On DemandKNX News On Demand

New results offer hope for treating Alzheimer's Disease

View descriptionShare

KNX News On Demand

KNX: On-Demand    
2,313 clip(s)
Loading playlist

The latest results involving an experimental drug have some promising findings when it comes to treating Alzheimer's Disease. Phase 3 trial data shows lecanemab after 18 months was associated with more clearance of amyloid and less cognitive decline.

While the findings offer hope, they also raise safety concerns because of the drug's association with some serious adverse effects. Susan Howland is program director of the Alzheimer's Association California Southland chapter. And Tony Gonzales is an Alzheimer’s Association National Early-Stage Advisor. He was diagnosed with mild cognitive impairment at age 47 last year.   

 

  • Facebook
  • Twitter
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

  1. KNX News On Demand

    2,313 clip(s)

KNX News On Demand

KNX: On-Demand    
Social links
Follow podcast
Recent clips
Browse 5,503 clip(s)